Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Wally R. Smith, Bogdan Dumitriu et al.|The Lancet Haematology|2024Cited by 25